Norgine Ventures

The firm invests directly from Norgine's corporate balance sheet, allowing it to provide growth-stage venture debt alongside minority equity stakes. This structure means it does not raise external funds or operate under fixed fund-life constraints, giving portfolio companies a capital partner that can hold positions indefinitely.

Norgine Ventures is the dedicated investment arm of Norgine, a private European pharmaceutical company founded over a century ago. The Ventures unit deploys the parent company's capital into external healthcare innovations, while portfolio companies may also benefit from Norgine's commercial infrastructure and regulatory expertise in European markets.

The firm focuses on biopharmaceutical, medical device, diagnostic, and digital health companies at clinical or commercial inflection points. Investments typically support companies advancing therapies through Phase II or III clinical trials, scaling manufacturing, or pursuing European regulatory approvals.

Norgine Ventures commonly provides venture debt as a complement to equity rounds led by traditional venture capital firms. This hybrid approach gives companies non-dilutive growth capital while Norgine takes minority equity exposure, allowing founders and existing investors to retain control.

The firm writes checks generally ranging from €5 million to €20 million, concentrating on companies headquartered in Western Europe. It has also evaluated opportunities in Israel and the Nordic region, reflecting the broader European footprint of its parent company's commercial operations.